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This study examined the status of KRAS and BRAF mutations, in relation to extracellular signal-regulated protein kinase (ERK)
activation in 58 ovarian carcinomas to clarify the clinicopathological and prognostic significance of KRAS/BRAF mutations. Somatic
mutations of either KRAS or BRAF were identified in 12 (20.6%) out of 58 ovarian carcinomas. The frequency of KRAS/BRAF mutations
in conventional serous high-grade carcinomas (4.0%:1/25) was significantly lower than that in the other histological type (32.3%:
10/31). Phosphorylated ERK1/2 (p-ERK1/2) expression was identified in 18 (38.2%) out of 45 ovarian carcinomas. KRAS/BRAF
mutation was significantly correlated with International Federation of Gynecology and Obstetrics (FIGO) stage I, II (Po0.001), and
p-ERK1/2 (Po0.001). No significant correlations between KRAS/BRAF mutations or p-ERK1/2 expression and overall survival were
found in patients with ovarian carcinoma treated with platinum and taxane chemotherapy (P¼0.2460, P¼0.9339, respectively).
Next, to clarify the roles of ERK1/2 activation in ovarian cancers harbouring KRAS or BRAF mutations, we inactivated ERK1/2 in
ovarian cancer cells using CI-1040. Cl-1040 is a compound that selectively inhibits MAP kinase kinase (MEK), an upstream regulator of
ERK1/2, and thus prevents ERK1/2 activation. Profound growth inhibition and apoptosis were observed in CI-1040-treated cancer
cells with mutations in either KRAS or BRAF in comparison with the ovarian cancer cells containing wild-type sequences. This was
evident in both in vitro and in vivo studies. The findings in this study indicate that an activated ERK1/2 pathway is critical to tumour
growth and survival of ovarian cancers with KRAS or BRAF mutations. Furthermore, they suggest that the CI-1040-induced
phenotypes depend on the mutational status of KRAS and BRAF in ovarian cancers. Therefore, ovarian cancer patients with KRAS or
BRAF mutations may benefit from CI-1040 treatment.
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Ovarian carcinoma is the most lethal malignant disease in
American women (Wingo et al, 1995) and the most lethal
gynaecological cancer in Japan. Its frequency has increased
dramatically in the last decade. In more than 70% of patients with
ovarian carcinoma, there is evidence of tumour dissemination
beyond the ovaries at diagnosis. In these cases, combined
treatment with surgery and chemotherapy is necessary. First-line
chemotherapy with platinum drugs and taxanes yields a response
rate of over 80%, but almost all patients relapse. Although there are
well-established surgical and chemotherapeutic treatments for
ovarian cancer, there is a significant opportunity to develop drugs
targeting specific molecular pathways. Drugs of this type would be
particularly useful for recurrent disease that has acquired
chemoresistance. Thus, there is a need for an improved under-
standing of the molecular pathways of ovarian carcinogenesis.
Several genetic alterations are associated with ovarian carcino-
genesis. The most frequent genetic abnormalities in ovarian
carcinoma are mutations in KRAS, BRAF, and p53 (Singer et al,
2003; Nakayama et al, 2006).
Mutations of either BRAF or KRAS lead to constitutive
activation (phosphorylation) of their downstream target, mito-
gen-activated protein kinase (MAPK), also known as extracellular
signal-regulated protein kinase (ERK) (Olson and Hallahan, 2004;
Wan et al, 2004). Mutations in BRAF or KRAS are correlated with
overexpression of activated ERK1/2 in ovarian serous tumours
(Hsu et al, 2004). Activation of ERK1/2 in turn activates
downstream cellular targets (Peyssonnaux and Eychene, 2001;
Allen et al, 2003) including a variety of cellular and nuclear
proteins. Although the functions of the RAS–RAF–MEK–ERK
pathway and its downstream effectors have been recently explored,
only the serous type of ovarian cancer has been studied (Hsu et al,
2004; Pohl et al, 2005). In addition, the biological role of this
pathway in the development of ovarian cancers of other
histological types is unknown.
Activating KRAS and BRAF mutations typically show mutant
exclusivity in tumours (Brose et al, 2002; Davies et al, 2002;
Gorden et al, 2003; Singer et al, 2003).
A large proportion of microsatellite-stable colorectal tumour
metastases has been shown to accumulate BRAF/KRAS mutations
(Oliveira et al, 2007). This suggests an epistatic relationship in
which either mutation is sufficient to deregulate a common
effector pathway, such as the MAP kinase kinase (MEK)–ERK
kinase cascade. If this is the case, tumours arising as a result of a
mutation in either KRAS or BRAF should harbour similar
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sdownstream dependencies. These might represent useful thera-
peutic targets in ovarian cancer. To test this hypothesis, we
examined the consequences of MEK–ERK pathway inhibition
using a highly potent and selective inhibitor of MEK1/2, CI-1040
(formerly known as PD184352) (Schaeffer and Weber, 1999;
Sebolt-Leopold et al, 1999, 2003; Sebolt-Leopold, 2004). The
inhibitor was tested in a collection of ovarian cancer cell lines
that showed differing mechanisms of MAP kinase pathway
deregulation.
MATERIALS AND METHODS
Tissue samples
Formalin-fixed, paraffin-embedded tissue samples of 58 ovarian
cancers, including 27 serous carcinomas, 20 mucinous carcinomas,
and 11 endometrioid carcinomas were used in this study. These
samples were obtained from the Department of Obstetrics and
Gynecology at the Shimane University Hospital. Diagnosis was
based on conventional morphological examination of sections
stained with haematoxylin and eosin (H&E) staining, and tumours
were classified according to the WHO (World Health Organiza-
tion) classification. Tumour staging was carried out according to
the International Federation of Gynecology and Obstetrics (FIGO)
classification. The clinicopathological characteristics of the
patients included in this study are summarised in Table 1. All
the patients were primarily treated with cytoreductive surgery and
adjuvant platinum and taxane chemotherapy (CBDCA AUC5,
Paclitaxel 175mgm
 2 or Docetaxel 70mgm
 2). All the cases
received 6–12 courses of this regimen. The acquisition of tumour
tissues was approved by the Shimane University Institutional
Review Board. The paraffin tissue blocks were organised into
tissue microarrays, which were made by removing 3mm diameter
cores of tumour from each block. The areas for coring were
selected by surgical pathologists (MF) on the basis of a review of
the H&E slides.
Cell culture and cell lines
OVCAR3, SKOV3, A2780, MDAH2774 (serous carcinoma), and
ES2 (clear cell carcinoma) human ovarian cancer cell lines were
obtained from the American Tissue Culture Center (Rockville, MD,
USA). The human ovarian carcinoma cell line KF28 (serous
carcinoma) was a kind gift from Dr Yoshihiro Kikuchi (Ohki
Memorial Kikuchi Cancer Clinic for Women, Saitama, Japan)
(Yamamoto et al, 2000). The MPSC1 cell line was established from
a low-grade serous carcinoma and was a kind gift from Dr le-Ming
Shih (Johns Hopkins Medical Institutions, Baltimore, MD, USA).
OVK#18 (serous carcinoma) human ovarian cancer cell line was
obtained from Tohoku University (Sendai, Japan). OMC3 (muci-
nous carcinoma) and JHOC5 (clear cell carcinoma) human ovarian
cancer cell lines were also obtained from Riken Bioresource Center
(Ibaragi, Japan). In addition, human papillomavirus E6/E7-
immortalised primary cultures of normal ovarian surface epithe-
lium (OSE) were also included in this study. IOSE27, a normal OSE
cell line, was obtained from the American Tissue Culture Center.
OSE7 and OSE10 normal OSE cell lines were a kind gift from Dr
Hidetaka Katabuchi (Kumamoto University, Kumamoto, Japan).
A set of primary cultures was established from ovarian cancers,
including POC-1, POC-2, and POC-3. The acquisition of anon-
ymous tissue specimens was approved by the Shimane University
Institutional Review Board.
The diagnoses were confirmed by a surgical pathologist before
the tumour samples were harvested for experiments. Primary
tumour cultures were established from freshly isolated tumour
samples by immunosorting or trypsinisation. For immunosorting,
fresh tumour tissues were minced and incubated with collagenase
Table 1 Mutational status of KRAS and BRAF genes and p-ERK1/2
expression in ovarian cancer
Case no. Histology Grade KRAS BRAF p-ERK1/2
1 Serous 1 WT WT N
2 Serous 1 WT T1796A/
V600E
P
3 Serous 2 WT WT N
4 Serous 3 WT WT N
5 Serous 3 WT WT N
6 Serous 2 WT WT P
7 Serous 2 WT WT N
8 Serous 2 WT WT P
9 Serous 3 WT WT N
10 Serous 3 WT WT P
11 Serous 3 WT WT P
12 Serous 3 WT WT N
13 Serous 3 WT WT N
14 Serous 3 G35T/
G12V
WT P
15 Serous 3 WT WT N
16 Serous 3 WT WT N
17 Serous 3 WT WT N
18 Serous 3 WT WT P
19 Serous 3 WT WT N
20 Serous 3 WT WT N
21 Serous 3 WT WT N
22 Serous 3 WT WT P
23 Serous 3 WT WT P
24 Serous 3 WT WT N
25 Serous 3 WT WT N
26 Serous 3 WT WT P
27 Serous 3 WT WT P
28 Mucinous 1 WT T1796A/
V600E
P
29 Mucinous 1 G35A/
G12D
T1796A/
V600E
P
30 Mucinous 1 WT WT N
31 Mucinous 1 WT T1796A/
V600E
P
32 Mucinous 1 G35T/
G12V
WT P
33 Mucinous 2 WT WT N
34 Mucinous 2 WT WT N
35 Mucinous 2 G35A/
G12D
WT P
36 Mucinous 2 WT WT N
37 Mucinous 2 WT WT N
38 Mucinous 2 WT WT N
39 Mucinous 2 WT WT N
40 Mucinous 2 WT WT P
41 Mucinous 3 WT WT P
42 Mucinous 3 WT WT N
43 Mucinous 3 WT WT N
44 Mucinous 3 WT WT N
45 Mucinous 3 WT WT N
46 Mucinous 3 WT WT P
47 Mucinous 3 WT WT N
48 Endometrioid 1 WT T1796A/
V600E
P
49 Endometrioid 1 WT WT N
50 Endometrioid 2 WT WT P
51 Endometrioid 2 WT WT N
52 Endometrioid 2 G35A/
G12D
WT P
53 Endometrioid 2 G35A/
G12D
WT P
54 Endometrioid 2 G35T/G12V WT P
55 Endometrioid 3 G35A/G12D WT P
56 Endometrioid 3 WT WT N
57 Endometrioid 3 WT WT P
58 Endometrioid 3 WT WT N
N¼negative; P¼positive; WT¼wild type.
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 1)a t3 7 1C for 40min. After filtration through sieve
membranes (with 100mm pores), tumour cells were immunosorted
using an epithelial specific antigen (Ep-CAM) antibody bound to
Dynalt beads (Dynal, Oslo, Norway) following the vendor’s
instructions (Nakayama et al, 2006). Freshly isolated tumour cells
were allowed to grow in culture and were used for experiments
within two passages.
Mutational analysis of KRAS and BRAF
Genomic DNA was purified from all the cell lines and formalin-
fixed, paraffin-embedded tissues using a Qiaquick polymerase
chain reaction (PCR) purification kit (Qiagen, Valencia, CA, USA).
PCR was then carried out followed by nucleotide sequencing using
the iCycler (Bio-Rad, Hercules, CA, USA). Exon 1 of KRAS and
exon 15 of BRAF were both sequenced, as these mutational hot
spots together harbour nearly all published mutations (Davies
et al, 2002; Singer et al, 2002, 2003; Sieben et al, 2004). The primers
for PCR and sequencing were manufactured by GeneLink
(Hawthorne, NY, USA), and their sequences were described in
an earlier report (Nakayama et al, 2006). The sequences were
analysed using the Lasergene programme, DNASTAR (Madison,
WI, USA).
Immunohistochemistry
Expression of the active phosphorylated ERK1/2 (p-ERK1/2) was
assessed by immunohistochemistry and western blot analysis. The
antibody used in this study was a rabbit polyclonal antibody that
reacted with phosphorylated but not unphosphorylated ERK1/2
(Cell Signaling Technology). Immunohistochemistry was carried
out on tissue microarrays at a dilution of 1:1000 followed by
detection with the En Visionþ System using the peroxidase
method (DAKO, Carpinteria, CA, USA). The percentage of positive
cells was estimated by randomly counting B500 tumour cells from
three different high-power fields ( 40) within one specimen. A
positive reaction was defined as a discrete localisation of the brown
chromagen in the nucleus or cytoplasm. Cases in which more than
5% of the tumour cells showed detectable immunoreactivity were
scored as positive.
Western blot analysis
Cell lysates were prepared by dissolving cell pellets in Laemmli
sample buffer (BioRad, Hercules, CA, USA) supplemented with 5%
b-mercaptoethanol (Sigma, St Louis, MO, USA). Western blot
analysis was performed on ovarian cancer/OSE cell lines/cultures,
including OVCAR3, SKOV3, A2780, MDAH2774, ES2, MPSC1,
KF28, OVK#18, OMC3, JHOC5, PC1, PC2, PC3, IOSE29, OSE7, and
OSE10. Similar amounts of total protein from each lysate were
loaded and separated on 10% Tris-Glycine-SDS polyacrylamide
gels (Novex, San Diego, CA, USA) and electroblotted to Millipore
Immobilon-P polyvinylidene difluoride membranes. The mem-
branes were probed with an active ERK1/2 antibody (pTEpY,
1:5000) (Cell Signaling Technology) followed by a peroxidase-
conjugated anti-mouse or anti-rabbit immunoglobulin (1:20000).
The same membrane was probed with an antibody that reacted
with total ERK1/2 (1:5000) (Cell Signaling Technology) for loading
controls. Western blots were developed by chemiluminescence
(Pierce, Rockford, IL, USA).
Cell-growth assays
For the cell-growth assay, cells were plated at the same density
(3 10
3 cells per well) in 96-well plates. An methyl thiazoyl
tetrazorium (MTT) cell-growth assay was performed (Nakayama
et al, 2001) 96h after treating the cells with CI-1040 (provided by
Pfizer, Inc., New York, NY, USA) at 5mM or with dimethyl
sulphoxide (DMSO) (control). The data were expressed as a
percentage of the DMSO control. The mean and standard deviation
(s.d.) were obtained from three experiments. Apoptotic cells were
detected with 4’,6-diamidino-2-phenylindole (DAPI) staining. The
data were expressed as the mean ±1 s.d. from triplicates. To
confirm the presence of apoptotic cells, DAPI-stained cells were
also stained with Annexin V dye. Bromodeoxyuridine (BrdUrd)
uptake and staining were measured using a cell proliferation kit
(Amersham, Buckinghamshire, England, UK) and apoptotic cells
were detected using an Annexin V staining kit (Bio Vision,
Mountain View, CA, USA). The percentages of BrdUrd-positive
and Annexin V-positive cells were determined by counting
approximately 400 cells from each well in 96-well plates. The data
were expressed as the mean ±1 s.d. of triplicates.
Tumour xenograft in nude mice
To confirm the findings of a CI-1040 effect in vitro, we injected
3 10
6 MDAH2774 or SKOV3 cells into the intraperitoneal tissue
of nu/nu mice (4 weeks of age). Four weeks BALB/c nu/nu mice
were purchased from Charles River Japan Inc. (Kanagawa, Japan).
CI-1040 was prepared in a vehicle of 10% Cremophore EL (Sigma,
St Louis, MO, USA), 10% ethanol, and 80% water. When the model
for the mouse study was first designed, the end point was set to be
the day when the mice began to produce ascites, or acute gain of
weight due to tumour growth, for reasons of ethical origin.
Tumours that start causing ascites have a chance of developing
other malignant characteristics, which can become harmful
progressively. Four mice were used for each experimental group.
During the study, the mice were killed when it was discovered that
the abdomen of one of the mice had begun to distend because of
ascites. One week after tumour-cell injection, either CI-1040 (CI-
1040, 150mgkg
 1, resuspended in 10% Cremophore EL (Sigma),
10% ethanol, and 80% water) or a vehicle only (10% Cremophore
EL (Sigma), 10% ethanol, and 80% water) were injected
intraperitoneally (i.p.) once daily for 3 weeks. The total dose of
CI-1040 for each mouse was 63mg. Four weeks after the cell
injection (three weeks after CI-1040 injection), the abdomens of
the control group mice had begun to distend. The time for
termination of the experiment was dictated by the aforementioned
ethical reasons (tumour ascites in controls), and this endpoint was
observed at that time. We anaesthetised the mice before they were
rendered moribund by the experiment. The total tumour weight at
that time was around 500mg. Necropsy was carried out on all mice
to assess i.p. tumour growth, and the tumours were excised and
weighed. Animal experiments were carried out in accordance with
the regulations of the Institutional Ethical Commission (Shimane
University) and of the United Kingdom Co-ordinating Committee
on Cancer Research guidelines (Workman, 1998).
Statistical methods for clinical correlation
Overall survival was calculated from the date of diagnosis to the
date of death or last follow-up. Patients with either KRAS or BRAF
mutations had similar performance status distributions. The data
were plotted as Kaplan–Meier curves, and the statistical sig-
nificance was determined by the log-rank test. Data were censored
when patients were lost to follow-up. The Student’s t-test was used
to examine the statistical significance in the difference of growth-
assay data.
RESULTS
Identification of KRAS and BRAF mutations
The mutational status of KRAS and BRAF in all 45 ovarian
carcinomas is summarised in Table 1. Somatic mutations of KRAS
were identified in 8 (13.7%) out of 58 ovarian carcinomas. In
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scontrast, somatic mutations of BRAF were identified in 5 (8.6%)
out of 58 ovarian carcinomas. Somatic mutations of either KRAS or
BRAF were identified in 12 (20.6%) out of 58 ovarian carcinomas.
Most KRAS mutations were located at codon 12 and all BRAF
mutations at codon 600. Both of these codons are mutation hot
spots. Interestingly, simultaneous mutations of KRAS and BRAF
did not occur in the tested ovarian carcinomas with the exception
of one mucinous case.
A panel of ovarian cancer cell lines and primary cultures was
first analysed for tumour mutation status in the KRAS and BRAF
genes. As shown in Figure 1, three ovarian cancer cell lines
harboured either KRAS or BRAF mutations. The frequency of
either KRAS or BRAF mutations in conventional serous high-grade
carcinomas (4.0%:1/25) was significantly lower than in the other
histological type (32.2%:10/31).
Relationship between KRAS/BRAF mutations and
p-ERK1/2 expression or clinicopathological factors
The immunoreactivity of active p-ERK1/2 was detected in both the
nucleus and the cytoplasm of the tumour cells (Figure 2). This is
consistent with an earlier report (Mizumoto et al, 2007). Positive
active p-ERK1/2 was identified in 27 (46.6%) out of 58 ovarian
carcinomas. The patients were stratified into two groups depend-
ing on the mutational status of KRAS/BRAF. The relationships
between KRAS/BRAF mutations and clinicopathological factors,
including p-ERK1/2 expression are shown in Table 2. There was no
significant correlation between KRAS/BRAF mutations and the
patient’s age. The results in Table 2 show that KRAS/BRAF
mutation is correlated significantly with FIGO stage I, II
(Po0.001), and p-ERK1/2 (Po0.001). In addition, there were
significant correlations between KRAS/BRAF mutations and
pathological grade (P¼0.004), and histological subtype
(P¼0.014).
Effect of KRAS/BRAF mutations or p-ERK1/2 on the
prognosis of ovarian carcinomas
Next, we examined the prognostic effect of KRAS/BRAF mutations
and p-ERK1/2 expression. Out of the 58 samples that we examined,
45 were available for prognostic analysis. Kaplan–Meier estimates
of overall survival are plotted in Figure 3. There was no significant
relationship between KRAS/BRAF mutations or p-ERK1/2 expres-
sion and overall survival in patients with ovarian carcinoma
(P¼0.2460, P¼0.9339, respectively). Univariate analysis showed
that only FIGO stage III, IV affected the overall survival of patients
with ovarian carcinoma significantly(P¼0.014).
Effects of ERK1/2 inactivation on ovarian carcinoma
in vitro
A panel of ovarian cancer cell lines and primary cultures of ovarian
cancer were first analysed for KRAS and BRAF gene mutation
status. Mutational status was correlated with growth inhibition and
apoptosis induction by the MEK inhibitor CI-1040 that prevented
activation of the downstream target, ERK1/2. Western blot analysis
showed a dose-dependent effect on the expression of active ERK1/
2 in ES2 cells, and active ERK1/2 was not detectable 6h after
treating the cells with CI-1040 at a concentration of 5mM (Figure 4).
As shown in Figure 5, four of the tumours harbouring either KRAS
or BRAF mutations showed a marked reduction (o50% of DMSO
control) in the cell number in the CI-1040-treated group as
compared with the other 14 tumours containing wild-type KRAS
and BRAF (Po0.001). CI-1040 had no significant effect on the
growth of normal cells, including the OSE cells. It is likely that
KRAS/BRAF mutation is not the only determinant for activating
ERK1/2. Therefore, we analysed p-ERK1/2 expression in each of
the cell lines listed in Figure 5. Only four of these cell lines,
MDAH2774, ES2, MPSC1, and POC1, strongly expressed p-ERK1/2.
SKOV3 and A2780 showed weak expression of ERK1/2.These
results suggest that activation of ERK1/2 may depend on KRAS/
BRAF mutation in ovarian cancer cells.
To assess the mechanisms underlying growth inhibition by
CI-1040, we measured the percentages of BrdUrd-labelled cells and
Annexin V-labelled cells to estimate proliferation and apoptosis,
respectively. We found that CI-1040 significantly reduced cellular
proliferation and induced apoptosis in cell lines with either KRAS
or BRAF mutations in comparison with cell lines with wild-type
sequences (Figure 6, Supplementary Figure 1).
Effects of CI-1040 ERK1/2 inactivation on ovarian
carcinomas in vivo
On the basis of the above findings, we investigated whether
CI-1040 had a growth-inhibitory effect on tumour formation and
development in vivo. Tumour xenografts from both MDAH2774
(KRAS mutant) and SKOV3 (wild type of KRAS and BRAF) cell
KRAS BRAF
G to T mutation at nucleotide 35
(reverse strand)
T to A mutation at nucleotide 1796
(forward strand)
50 80 70 60
Figure 1 Chromatograms of KRAS and BRAF mutational status in three representative ovarian cancer cells. (A) Left panel (MDAH2774) showing a point
mutation in the KRAS gene. (B) Right panel (ES2) showing a point mutation in the BRAF gene. Arrows represent spike which indicates mutation.
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slines were established in a nu/nu mouse model. All mice injected
with CI-1040 developed significantly smaller intra-abdominal
xenograft tumours than the mice carrying diluent control cells of
the KRAS mutant cell line MADH2774 (Figure 7A). There were no
differences in intra-abdominal xenograft tumour weights between
the CI-1040-treated group and control groups transplanted with
the wild-type KRAS/BRAF cell line SKOV3 (Figure 7B). Histological
examination of the tumours after CI-1040 treatment showed
inactivation of p-ERK1/2 in tumour cells based on immunohisto-
chemistry (Figure 7C and D).
DISCUSSION
The significantly higher frequency of KRAS/BRAF mutations in
non-serous type carcinomas compared with conventional high-
grade serous carcinomas in this study is a finding of great interest.
It suggests that conventional high-grade serous and non-serous
tumours may be distinguished on the basis of characteristic
genetic alterations. In addition, this observation further supports
the theory that ovarian carcinoma arises from multiple pathways
(Shih Ie and Kurman, 2004, 2005). In this model, conventional
high-grade serous and non-serous carcinomas develop indepen-
dently from one another and are characterised by different
molecular genetic changes and gene expression profiles (Schwartz
et al, 2002; Marquez et al, 2005).
We reported earlier that KRAS or BRAF mutations were quite
common in low-grade serous ovarian carcinomas but rare in
conventional high-grade serous carcinomas (Nakayama et al,
2006). Our present results showing low frequencies of either KRAS
or BRAF mutations in conventional high-grade serous carcinoma
are consistent with our earlier reports (Nakayama et al, 2006).
V600E is the most common BRAF mutation in ovarian cancer
(Singer et al, 2003; Sieben et al, 2004; Shih Ie and Kurman, 2005;
Nakayama et al, 2006). However, mutations at E585K and G463E
have also been reported in ovarian cancer samples and cell lines
(Davies et al, 2002). Therefore, further studies are needed to clarify
the effects of other BRAF mutations in ovarian cancer, and to
completely describe the mutation profile of KRAS-BRAF signalling
in established ovarian cancer cell lines.
In this study, we also showed that the ERK–MAPK pathway was
activated in 15 (33.3%) out of 45 ovarian carcinomas and
activation depended on the mutational status of KRAS and BRAF.
This is in contrast with a recent report showing that this pathway
is frequently activated independent of the status of KRAS and
BRAF in endometrioid-type endometrial cancer (Mizumoto et al,
2007). This discrepancy may be because of differences in organ-
specific oncogenic pathways. The RAS–RAF–MEK–ERK pathway
may play an important role in ovarian carcinogenesis but not in
endometrial carcinogenesis. Similarly, alternative pathways for
ERK activation, such as crosstalk with the PI3K pathway, exist in
endometrial cancer but are rare in ovarian cancer. Indeed, PI3K
signalling by either PIK3CA or PTEN mutations occurs in 40% of
endometrial cancers but in o5% of ovarian cancers (Tashiro et al,
1997; Oda et al, 2005; Kolasa et al, 2006; Nakayama et al, 2006).
In this study, KRAS /BRAF mutations tended to have a
favourable but not statistically significant effect on overall survival.
Our findings contrast with a recent report showing a positive
correlation between a KRAS or BRAF mutation and clinical
aggressiveness in colorectal, non-small-cell lung, and thyroid
cancers (Lievre et al, 2006; Lee et al, 2007; Massarelli et al, 2007).
This difference in prognostic significance between ovarian cancer
and the latter types is intriguing, and it probably reflects organ-
specific roles of the KRAS/BRAF pathway. In this study, 8 out of 9
KRAS/BRAF mutations were identified in early stage (stage I, II)
tumours. This may reflect a more indolent course of tumours with
KRAS/BRAF mutations.
In an earlier report, advanced ovarian cancer patients (stage III,
IV) with p-ERK expression had a longer overall survival than
patients with low p-ERK values (Hsu et al, 2004). However, we did
not find a significant correlation between p-ERK expression and
overall survival in our study. This difference may be because of a
200 m 200 m
AB
Figure 2 Immunohistochemical staining of phosphorylated extracellular-regulated kinase (p-ERK1/2). (A) Intense immunoreactivity is present in both the
nucleus and the cytoplasm in this ovarian carcinoma. (B) A case with negative staining of phosphorylated ERK1/2 (p-ERK1/2).
Table 2 Association between KRAS/BRAF mutational status and clinico-
pathological factors in patients with ovarian cancer
KRAS/BRAF mutation
Factors Patients Negative Positive P-value
FIGO stage
I, II 18 8 10 o0.001
III, IV 38 38 2
Grade
G1 9 3 6 o0.001
G2, G3 49 43 6
Histology
Serous 28 26 2 0.014
Others 30 20 10
Age (years)
o60 35 28 7 0.293
X60 23 17 6
p-ERK1/2
Positive 27 15 12 o0.001
Negative 31 31 0
FIGO, International Federation of Gynecology and Obstetrics; MAPK, mitogen-
activated protein kinase; ERKV2, Extracellular signal-regulated protein kinases1/2.
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and mucinous histology tumours being included in this study as
compared with the earlier study.
Although the biological roles of the RAS–RAF–MEK–ERK
pathways in human cancer have been thoroughly investigated,
there have been no recent studies. Therefore, it is not known
whether the activation of KRAS or BRAF mutations alters the
effects of these pathways on tumour progression. In this study,
we carried out a genotype–phenotype correlation of ovarian
cancer cells using a MEK inhibitor, CI-1040. In this study, we
focussed on CI-1040 because it inhibited the common downstream
target in the RAS signalling pathway. Therefore, CI-1040 has the
potential to be developed into a drug for the treatment of
ovarian carcinomas in patients with either KRAS or BRAF
mutations. An oral formulation of CI-1040 had already been
shown to be an effective MEK inhibitor and was generally well
tolerated in a multicentre phase II study (Rinehart et al, 2004).
Our results provide compelling evidence that the biological effects
of the ERK signalling pathway depend on the mutational status
of its upstream regulators, (i.e.), the KRAS and BRAF genes.
Ovarian carcinomas with mutations in either KRAS or BRAF
were more sensitive to growth inhibition and apoptosis induction
by the MEK inhibitor, CI-1040. This observation suggests that
ovarian carcinomas with mutations in either KRAS or BRAF are
more highly dependent on the activation of the RAS–RAF–MEK–
ERK pathway for cell proliferation and survival than those without
such mutations. Thus, inactivation of ERK1/2 results in marked
growth inhibition in ovarian carcinomas with mutations in
KRAS or BRAF in comparison with only a modest effect on wild-
type tumours. The above observations lend strong support to the
view of ‘kinase addiction’ by which the activating mutations in the
kinase pathway confer susceptibility of the tumours to an inhibitor
(Sebolt-Leopold et al, 1999; Arteaga and Baselga, 2004). In
microsatellite-unstable colorectal cancer cell lines, the effect of
BRAF inhibition depended on whether the cell harboured a BRAF
or a KRAS mutation. BRAF inhibition by small interfering RNA
resulted in significantly decreased proliferation and increased
apoptosis in the BRAF mutant lines. In contrast, this effect was not
seen in the KRAS mutant lines (Preto et al, 2008). Cells carrying
BRAF mutations have also been shown to be more sensitive to
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Figure 4 Western blot analysis. Expression of phosphorylated ERK1/2 (p-ERK1/2) is undetectable in all CI-1040-treated samples. A similar amount of
protein was loaded in CI-1040 and DMSO-treated samples as evidenced by a similar intensity of total ERK1/2. D, DMSO treatment, C, and CI-1040
treatment.
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Figure 3 Kaplan–Meier survival curve in 45 patients with ovarian carcinoma according to KRAS/BRAF mutation and phosphorylated ERK (p-ERK)
expression. (A) KRAS/BRAF mutational status correlates with favourable overall survival in patients with ovarian carcinoma. (B) p-ERK1/2 expression does
not correlate with shorter overall survival in patients with ovarian carcinoma.
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Figure 7 Effects of CI-1040 in a mouse xenograft model. (A) CI-1040-treated cells produced small tumour nodules in the peritoneal cavity. However, the
diluent control-treated cells grew much larger i.p. tumours in KRAS mutant MDAH2774 cells. (B) In contrast, there were no differences in tumour weights
between CI-1040-treated cells and control-treated cells in wild-type (WT) KRAS/BRAF SKOV3 cells. Tumours were excised and weighed. The data are
expressed as the total tumour weight from each mouse. (C and D) Immunohistochemical staining of phosphorylated extracellular-regulated kinase 1/2 (p-
ERK1/2) in tumours with KRAS mutant MDAH2774 cells. (C) Intense immunoreactivity is present in both the nucleus and the cytoplasm in CI-1040-
untreated tumour. (D) Immunoreactivity is absent in both the nucleus and the cytoplasm in CI-1040-untreated tumour cells.
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Figure 6 Detection of apoptotic cells and proliferation cells. (A) The CI-1040-treated ES2 cells, but not KF28 cells, show morphological features typical of
apoptosis. (B) Apoptotic cells are quantified by counting them under a fluorescent microscope. (C) Treatment with CI-1040 decreases DNA synthesis as
measured by BrdUrd uptake in ES2 cells, but not KF28 cells. (D) Proliferation is estimated by counting BrdUrd-stained cells under a fluorescent microscope.
The experiment was performed 72h after CI-1040 or DMSO treatment.
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This raises the possibility that KRAS and BRAF mutant cancer cells
might be differentially dependent on signalling mechanisms that
involve MEK. This difference in sensitivity to the RAS–RAF–
MEK–ERK pathway between ovarian cancer and the latter types is
intriguing, and it probably reflects organ-specific roles of the
KRAS and BRAF oncogenes.
In light of our in vivo and in vitro findings, we propose that
ovarian cancer patients with KRAS or BRAF mutations be
considered for MEK inhibitor (CI-1040) therapy if they recur after
conventional platinum and taxane chemotherapy.
Thus far, the MEK inhibitor CI-1040 has fared poorly in clinical
trials for breast, colon, and lung cancer (Rinehart et al, 2004).
However, its favourable therapeutic index and high selectivity may
outweigh its shortcomings in KRAS and BRAF mutant ovarian
cancer. Therefore, we recommend that in further clinical trials of
MEK inhibitors for ovarian cancer, patients are stratified on the
basis of KRAS/BRAF mutational status.
In summary, we have shown that the phenotypic change in
ovarian carcinomas in response to ERK1/2 inactivation depends
on the mutational status of KRAS and BRAF. The findings in this
study provide new insight into the biological roles of the RAS–
RAF–MEK–ERK signalling pathway in ovarian carcinomas. In
addition, our observations have an important therapeutic implica-
tion in ovarian cancer patients with KRAS or BRAF mutations.
Ovarian carcinomas with KRAS or BRAF mutation are clinically
low-grade carcinomas of serous or other histological subtypes that
are often refractory to conventional cytotoxic chemotherapy
(Bristow et al, 2002a,b; Winter et al, 2007). Therefore, detection
of KRAS and BRAF mutations in ovarian cancers may identify
patients who will benefit from CI-1040 therapy.
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